Telix Pharmaceuticals (TLX) to Announce Earnings on Thursday

Telix Pharmaceuticals (NASDAQ:TLX) is expected to be posting its H1 2026 results before the market opens on Thursday, August 20th. Analysts expect the company to post earnings of $0.0447 per share and revenue of $479.6290 million for the quarter. Interested persons are encouraged to explore the company’s upcoming H1 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 7:00 PM ET.

Telix Pharmaceuticals Price Performance

TLX stock opened at $11.73 on Tuesday. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $12.60. The firm’s 50-day moving average is $10.77 and its two-hundred day moving average is $9.54. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $975,000. Jane Street Group LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth about $564,000. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth about $213,000. Rhumbline Advisers lifted its stake in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in Telix Pharmaceuticals during the third quarter valued at about $243,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Citigroup decreased their price objective on shares of Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a report on Tuesday, July 7th. Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Friday, July 17th. Finally, Royal Bank Of Canada cut Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.